3 Dividend Stocks Better Than Pfizer, Inc.

Pfizer (NYSE: PFE) recently reported third-quarter earnings that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's performance does little to encourage dividend investors that the company will return to profit growth next year, so let's consider three other dividend-paying drugmakers that may be better positioned next year to boost their dividend payout.

While Pfizer's top and bottom line are struggling, Novartis' (NYSE: NVS) sales and earnings are growing. Amgen's (NASDAQ: AMGN) 1.7% forward dividend yield may appear uninspiring versus Pfizer's 3.6% yield, but investors may find that Amgen is far better positioned to grow its payout than Pfizer is. Diabetes powerhouse Novo Nordisk's (NYSE: NVO) biggest benefit may be its market-leading position in one of the world's fastest-growing indications.

Source: Motley Fool

Related Articles:
- 4 Higher Yielding Basic Materials Stocks With Growing Dividends
- 7 Dividend Growth Stocks That Could Make You Wealthy
- 12 High-Yield Managed Distribution Policy Funds
- The 2013 Elite Dividend Stocks List
- 6 High-Yield Dividend Achievers With 25 Years of Increases